Skip to main content

Table 2 Baseline patient demographics and clinical characteristics of the modified full analysis set

From: Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B

Characteristic Micafungin Liposomal amphotericin B Total
  Non-ICU (n = 127) ICU (n = 120) Non-ICU (n = 136) ICU (n = 110) Non-ICU (n = 263) ICU (n = 230)
Age (years)       
Mean ± standard deviation 53.1 ± 16.90 52.4 ± 19.40 53.7 ± 18.74 53.4 ± 17.76 53.4 ± 17.85 52.9 ± 18.60
   Median 54.0 54.5 55.5 56.0 55.0 56.0
   Range 18.0 to 87.0 18.0 to 89.0 16.0 to 89.0 17.0 to 97.0 16.0 to 89.0 17.0 to 97.0
Male, n (%) 79 (62.2) 76 (63.3) 79 (58.1) 68 (61.8) 158 (60.1) 144 (62.6)
Female, n (%) 48 (37.8) 44 (36.7) 57 (41.9) 42 (38.2) 105 (39.9) 86 (37.4)
Race, n (%)       
   Black 11 (8.7) 2 (1.7) 7 (5.1) 3 (2.7) 18 (6.8) 5 (2.2)
   Caucasian 84 (66.1) 65 (54.2) 97 (71.3) 56 (50.9) 181 (68.8) 121 (52.6)
   Other 32 (25.20) 53 (44.17) 32 (23.5) 51 (46.4) 64 (24.3) 104 (45.2)
Region, n (%)       
   Brazil 37 (29.1) 18 (15.0) 42 (30.9) 15 (13.6) 79 (30.0) 33 (14.3)
   Europe 37 (29.1) 46 (38.3) 43 (31.6) 34 (30.9) 80 (30.4) 80 (34.8)
   India 12 (9.4) 44 (36.7) 20 (14.7) 39 (35.5) 32 (12.2) 83 (36.1)
   North America 11 (8.7) 6 (5.0) 12 (8.8) 7 (6.4) 23 (8.7) 13 (5.7)
   Other 30 (23.6) 6 (5.0) 19 (14.0) 15 (13.6) 49 (18.6) 21 (9.1)
APACHE II score       
   Mean ± standard deviation 13.4 ± 6.32 18.4 ± 9.39 14.1 ± 6.60 17.8 ± 9.35 13.8 ± 6.46 18.1 ± 9.35
   Median 13.0 19.0 14.0 17.0 14.0 17.5
   Range 0 to 30.0 0 to 44.0 0 to 37.0 0 to 47.0 0 to 37.0 0 to 47.0
Relevant risk factors       
   Catheter present 95 (75.4) 116 (96.7) 93 (68.4) 105 (95.5) 188 (71.8) 221 (96.1)
   Bone marrow transplant 4 (3.1) 2 (1.7) 2 (1.5) 1 (0.9) 6 (2.3) 3 (1.3)
   Neutropenia 26 (20.5) 6 (5.0) 21 (15.4) 4 (3.6) 47 (17.9) 10 (4.3)
   Persistent neutropenia during therapy 11 (8.8) 3 (2.5) 7 (5.3) 2 (1.9) 18 (7.0) 5 (2.2)
   Acute leukemia 20 (15.7) 1 (0.8) 13 (9.6) 3 (2.7) 33 (12.5) 4 (1.7)
   Hematological disorder 37 (29.1) 7 (5.8) 24 (17.6) 8 (7.3) 61 (23.2) 15 (6.5)
   Liver disorder/failure 1 (0.8) 0 (0.0) 2 (1.5) 0 (0.0) 3 (1.1) 0 (0.0)
   Pancreatitis 5 (3.9) 4 (3.3) 3 (2.2) 6 (5.5) 8 (3.0) 10 (4.3)
   Renal disorder/failure 0 (0.0) 2 (1.7) 1 (0.7) 0 (0.0) 1 (0.4) 2 (0.9)
   Solid organ tumor 23 (18.1) 12 (10.0) 27 (19.9) 23 (20.9) 50 (19.0) 35 (15.2)
   Solid organ transplant 4 (3.1) 9 (7.5) 5 (3.7) 4 (3.6) 9 (3.4) 13 (5.7)
Antibiotic use 23 (18.1) 29 (24.2) 28 (20.6) 35 (31.8) 51 (19.4) 64 (27.8)
   Corticosteroid therapy 14 (11.0) 22 (18.3) 20 (14.7) 17 (15.5) 34 (12.9) 39 (17.0)
   Other immunosuppression 9 (7.1) 11 (9.2) 8 (5.9) 7 (6.4) 17 (6.5) 18 (7.8)
   Intravenous line/device 40 (31.5) 26 (21.7) 35 (25.7) 20 (18.2) 75 (28.5) 46 (20.0)
Length of hospital stay       
   Mean ± standard deviation 21.6 ± 17.77 20.0 ± 20.36 23.2 ± 20.35 27.6 ± 47.59 22.5 ± 19.13 23.6 ± 36.16
   Median 18.0 14.0 19.5 15.0 19.0 14.5
   Range 2 to 82.0 1 to 126.0 1 to 97.0 1 to 388.0 1 to 97.0 1 to 388.0
  1. APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.